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Since many years, clinical decisions about the management of patients with carotid stenosis have been based on the distinction
between “asymptomatic” and “symptomatic” presentations. This was also reﬂected by the design of previous studies on the
surgical versus conservative treatment and of current studies on interventional treatment versus surgery. Both terms, however,
only address diﬀerent phases of activity of the one and the same condition and blur the signiﬁcant message that carotid stenosis
is a most important marker of systemic atherosclerosis, which is accompanied by a much higher risk of cardiovascular events
rather than stroke. As a consequence, early diagnosis and followup during best medical treatment, life-style management, regular
cardiovascular assessment, and good control of all vascular risk factors should be recommended in all patients with carotid
stenosis—whether identiﬁed in the long-lasting “silent” or short-lasting “vulnerable” period lasting only a few weeks after cerebral
ischemia. Patients in this short time window beneﬁt from additional carotid intervention, under the condition of an individually
favorable beneﬁt-risk ratio (“individual vulnerability”).
1.Introduction
Carotid stenosis is common, especially in patients with
vascularriskfactorsorwithcoexistentpathologyofcoronary
or peripheral arteries [1, 2]. Since many decades, the
classiﬁcation between “symptomatic” and “asymptomatic”
carotid stenosis has dominated the management of aﬀected
patients. This distinction corresponds to the design and
results of previous clinical trials on surgical versus medical
treatment of carotid stenosis for stroke prevention as well
as of current studies comparing surgical with interventional
procedures (angioplasty with or without stent) [3–8].
However, careful review of these studies, as well as long-
term natural history observations for many decades, shows
that carotid stenosis is much more sensitive as marker of
systemic atherosclerosis than a cause of stroke [9, 10]. Only
within a small time window, when carotid stenosis shows
progression and high plaque vulnerability, either in the
presence of or without clinical signs or symptoms, there is
a higher incidence of stroke.
First descriptions of carotid stenosis related to cere-
brovascular events date back to T. Willis (1621–1675) and J.
J. Wepfer (1620–1695). However, it was not before the 1950s
when surgical interventions in the acute phase of stroke or
for secondary stroke prevention were reported by DeBakey
and Eastcott [11, 12].
In the 1980s, with the introduction of vascular ultra-
sound, the true dimensions of carotid disease became
apparent. Quite unsurprisingly, a high number of patients
were diagnosed with a so-called “asymptomatic” carotid
stenosis [2], but the prognosis and management of these
patients were totally uncertain. Studies performed since then
showed already very early an eminent contrast between a
very low incidence of stroke (1-2%/year) and a rather high
cardiovascular morbidity and mortality (5–10%/year), in
particular in patients with clinically silent presentation (so-
called “asymptomatic carotid disease”) [9, 10] .T h es a m ei s
true for the “symptomatic” carotid stenosis too, but with one
diﬀerence: there is a higher risk of stroke (10–20%) within
the ﬁrst 14–28 days following a cerebrovascular event (TIA2 Stroke Research and Treatment
or stroke) [13]. After this vulnerable period, the stroke risk
declines to that of the “asymptomatic” carotid stenosis.
2. Pathophysiology of CarotidStenosis
In most cases, carotid stenosis is the result of atherosclerotic
changesofthevesselwall.Othercauses(e.g.,dissection,often
observed in patients under 55 years of age) only account for
a small fraction of carotid lesions.
Atherosclerosis is a progressive disease with periods
of stability and sometimes reparation, which begins with
endothelial damage of the vessel wall already in infancy
and adolescence. There are many factors promoting this
damage: arterial hypertension, elevated blood lipid levels
and problems of cholesterol or glucose metabolism, reduced
release of nitrogen oxide, but also genetic components such
as expression of vascular cell adhesion molecules (VCAM-
1) [14–19]. Functional disturbance of laminar blood ﬂow,
particularly in arterial junctions, promotes the accumu-
lation of LDL and consecutively lead to remodeling of
the vessel wall. Monocyte migration and adhesion in the
region of endothelial damage then follows, induced by
proinﬂammatory cytokines [20, 21]. Identiﬁcation of these
mechanisms as biomarkers for the activity of atherosclerosis
has conﬁrmed the association of general risk factors with
vascular degeneration but unfortunately did not contribute
much to the sensitivity/speciﬁcity of a biomarker to predict
the individual stroke risk in a “vulnerable patient.”
3.DiagnosticMethods
Signiﬁcant improvements in diagnostic methods used for
detection of carotid stenosis have inﬂuenced our knowledge
about causes, spontaneous course, and risks of this disease.
Initially, auscultation of carotid bruits was the gold standard
in clinical practice. Systematic evaluation of this method,
however, revealed a very low speciﬁcity and sensitivity [2].
Digital subtraction angiography (DSA) was for a long time
the only method able to reliably identify a carotid stenosis,
but it was only used in preselected patients because of its
invasive nature and the risks associated with the procedure.
It was the introduction of vascular ultrasound, with its
noninvasive nature and good visualization, that made better
carotid screening possible in a large number of patients,
including many in clinically silent periods. Nowadays, highly
developed ultrasound systems allow visualization of vessel
wall changes in early stages, various grades of vessel stenosis
and of intraluminal ﬂow phenomena, as well as analysis of
plaque texture and structure in real time and 3D or even 4D
[22]. An experienced user can perform a highly sophisticated
and reliable examination, which can be repeated during
long-term monitoring without any risks or complications
for the patient. Such technologies have recently been intro-
duced in large clinical trials (e.g., PERFORM study) [23].
Ultrasound imaging can be used for screening and control
of intima-media thickness (IMT), plaque morphology, grade
and progression in clinical practice, as well as in clinical
and epidemiological studies [24, 25]. Today, DSA is only
rarely necessary—as opposed to the time when NASCET [3],
ECST [4] and ACAS [5] were carried out. In addition to
ultrasound, examinations such as CT and MR angiography
allow collection of supplementary diagnostic insights, for
example, perfusion studies, detection of vessel anomalies
(aneurysms, angiomas), and plaque imaging, and can also
be useful in cases where vessels are not well accessible via
ultrasound or as an alternative investigation [26, 27].
Despite these technical approaches and changes in diag-
nostic practice, the current classiﬁcation of the degree of
stenosis still corresponds to the modalities of angiographic
measurements used in the aforementioned clinical trials,
because they formed the basis for evidence-based regimens.
However, the information provided by ultrasound, CTA,
and MRA today is by far better for an individual decision
than the restricted use of only three stages of obstruction:
high grade (>75%), moderate (60–75%), and low grade
(<50% of local lumen reduction). If combined with other
parameters such as individual clinical presentation (“the
vulnerable patient”), modern brain imaging, and plaque
structure analysis (“the vulnerable plaque”), a best estima-
tion of the individual stroke risk associated with carotid
disease can be made regarding the therapeutic consequences.
These parameters allow a diﬀerentiation between “active”
(vulnerable plaques) and “stable” disease. Echomorphologic
features (plaque ulcerations, hemorrhage, lipid accumu-
lation), which can be identiﬁed through high-deﬁnition
ultrasound imaging and/or application of contrast agent,
correlate with histopathologic characteristics and signalize
a high risk for arterioarterial embolization [28]. HITS
(high-intensity transient signals) registered over the middle
cerebral artery indicate microembolization and can facilitate
the decision of individual treatment strategies with suitable
medication (CARESS [29]), as can detection of progressive
carotid stenosis or silent infarcts in cerebral CT/MRT be
interpreted as a sign of activity or acuity of a carotid stenosis
[30–32].
4. Studies
Most of our knowledge on the topic of carotid disease,
especially regarding treatment and course of the disease,
was derived from studies done in the last 25 years. Some
studied the natural history and reported clinical and vascular
followup, as did Chambers and Norris (1986) [9]a n d
Hennerici et al. (1987) [10].
As far as the so-called “symptomatic” carotid stenosis is
concerned, two major, multicenter, randomized controlled
studies are widely known: the North American Symptomatic
Carotid Endarterectomy Trial (NASCET) with 2885 patients
and the European Carotid Surgery Trial (ECST) with 3024
patients [3, 4].
The two randomized controlled studies mostly refer-
enced on the subject of “asymptomatic” carotid stenosis
are the Asymptomatic Carotid Atherosclerosis Study (ACAS)
with 1662 and the Asymptomatic Carotid Surgery Trial
(ACST) with 3120 patients [5, 6].
Table 1 summarizes the most important results of the
aforementioned studies [3–6, 33–38].Stroke Research and Treatment 3
Table 1: Outline of the most important characteristics and results of large carotid surgery trials. DSA: digital substraction angiography.
NASCET ECST ACAS ACST
n (total) 2885 3024 1662 3120
Observation period prior to inclusion
(max.)
120 days 180 days 120 days 180 days
Ratio TIA/stroke as qualifying event
prior to inclusion
61%/39% 50%/50% — —
Diagnostic method for determination
of stenosis grade (SG)
DSA (distal SG) DSA (local SG) Doppler
sonography/DSA
Duplex
sonography
Signiﬁcant correlation of stroke risk
with SG
Yes Yes No No
Controlled medical treatment No No No No
Indication for carotid surgery Limited at
50–69% SG >70–99% SG Limited at
50–69% SG >70–99% SG No
Limited at
>60–99%
Stroke risk (surgical treatment) (%) 15.7 (5 yrs) 8.9 (3 yrs) 15.0 (5 yrs) 10.5 (5 yrs) 5.1 (5 yrs) 6.4 (5 yrs)
Stroke risk (medical treatment) (%) 22.2 (5 yrs) 28.3 (3 yrs) 12.1 (5 yrs) 19.0 (5 yrs) 11.0 (5 yrs) 11.7 (5 yrs)
Absolute risk reduction (%) 6.5 19.4 −2.9 8.5 5.9 5.4
Relative risk reduction (%) 29 69 — 45 53 46
Numbers needed to treat 15 5 — 12 17 19
There is also a plethora of meta-analysis data available in
the literature [34, 36–38].
5. “Symptomatic” CarotidStenosis
In NASCET, the annual stroke rate under uncontrolled
medical treatment (within 2 years of followup) was 13%
for high-grade stenosis (>70% distal degree of stenosis)
and about 7% for moderate stenosis. Carotid occlusions
were found to be associated with a low risk of stroke
(2.1%/year for ipsilateral and 5.5%/year for all strokes) [3].
Therefore, carotid endarterectomy was not recommended
f o rl o wd e g r e eo fs t e n o s i s ,a sw e l la sf o rp a t i e n t so fs u b t o t a l
carotid stenosis (“pseudoocclusion”). The annual stroke rate
in ECST was up to 7% for high-grade stenosis (>90%
local degree of stenosis) in the—also uncontrolled—medical
treatment branch within a 3-year followup and as low as
1.5% for 70–89% local degree of stenosis [36, 39]. Both
studies recruited patients with a qualifying event (stroke,
TIA or retinal TIA, the latter being the case in about 1/3 of
NASCET patients) within a time window of 4 to 6 months
prior to recruitment. Many of these cerebrovascular events
were not evaluated with modern brain imaging (CT or
MRI),andtheassociationwiththecarotidstenosiswasmade
only based on patients’ histories. Other coincident potential
sources of stroke or TIA, such as lacunar infarcts due to
small vessel disease or cardioembolic infarcts from atrial
ﬁbrillation, were not taken into consideration [40], which is
a major drawback compared to modern clinical workup.
The results of both studies were interpreted as a signif-
icant advantage of carotid surgery over medical treatment,
which mainly consisted of acetylsalicylic acid, but lacked
systematic, prospective study design of other risk factor
management and monitoring of compliance during the
study.
Data in the literature indicates that relevant carotid
stenosis (>75%) is the underlying cause in only 5–12% of
a l lc e r e b r a li s c h e m i ce v e n t s[ 3, 4]: about 20% of strokes
in the territory of a “symptomatic” carotid stenosis cannot
be without any doubt attributed to carotid stenosis, for
example, in case of coexisting lacunar or cardioembolic
causes [41].
ThenewASCOstrokesubtypeclassiﬁcation[42]issuited
to display such coexisting stroke causes. We prospectively
studied 158 consecutive patients (89 men and 69 women,
mean age 75 ± 11 years) with carotid stenosis ≥50% (as
diagnosed on Doppler/Duplex vascular imaging) admitted
to our stroke unit in 2010 with the diagnosis of ischemic
stroke (142; 89.9%) or TIA (16; 10.1%), based on clinical
features and brain imaging (CT/MRI). Patients’ character-
istics, risk factors, and the distribution of the grades of the
232 carotid stenosis detected are displayed in Table 2.T h e
ASCO score (A: atherothrombosis; S: small vessel disease; C:
cardioembolism; O: other causes with corresponding grades:
(1) deﬁnitely a potential cause, (2) causality uncertain,
(3) disease present, but unlikely a cause, (0) no disease
present, and (9) no suitable tests performed) was used to
classify stroke etiology after a thorough stroke workup was
completed.
As determined by ASCO (Figure 1), carotid stenosis was
theprobablecauseoftheischemiceventonlyinlessthanhalf
of the patients recruited (grade A1; 65; 41.1%). However, in
17 patients (10.8%) this was combined with other equally
probable stroke causes (2; 3.1% S1 and 15; 9.5% C1).
Interestingly, only if degrees of stenosis ≥70% (78; 49.3%)
were considered, the majority of patients were identiﬁed
correctly. However, there were still 15 patients with A1 and4 Stroke Research and Treatment
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Figure 1: ASCO classiﬁcation of stroke etiologies. The ASCO classiﬁcation for “A” (atherothrombosis), “S” (small vessel disease), and
“C” (cardioembolic). The “O” (other causes) group was omitted because only 4 patients received a grade other than “0.” As all patients
had Duplex/Doppler imaging and carotid stenosis, no patient had “A0” or “A9,” so these groups were omitted. The ﬁgure visualizes
competing/coexisting etiologies.
Table 2: Patient characteristics.
Parameter Value %
Total of patients 158 100
Men 89 56.3
Women 69 43.7
Mean age (±SD) 75 ±11 —
Cerebral ischemia 142 89.9
TIA 16 10.1
Unilateral stenosis 84 53.2
Bilateral stenosis 74 46.8
Carotid stenosis grades
Carotid stenosis in total 232
≥50–59% 74 (31.9)
≥60–69% 68 (29.3)
≥70–79% 24 (10.3)
≥80–89% 28 (12.1)
≥90–99% 29 (12.5)
100% 9 (3.9)
Concomitant vascular diseases
Coronary artery disease 38 24.1∗
Peripheral artery disease 18 11.4
Vascular risk factors
Arterial hypertension 140 88.6
Hyperlipidemia 77 48.7
Diabetes mellitus 54 34.2
∗Correlation with stenosis grade: P<0.05.
C1 (9.5%). Cardioembolism was the most probable stroke
cause in 55 (34.8%) and small vessel disease in 17 (10.8%)
patients. Hence, 93 patients (58.9%) had an “asymptomatic”
carotid stenosis despite suggested acute stroke from carotid
stenosis.
6.“Asymptomatic” CarotidStenosis
Both natural history studies, as well as several large, mul-
ticenter, randomized controlled studies, have shown that
“asymptomatic” carotid stenosis is quite a benign disease,
with an annual stroke rate of only 1-2% and a stroke-related
annual mortality rate of merely <0.05% [5, 10].
Carotid stenosis, however, is an established risk factor
for myocardial infarction. The annual mortality, mainly
because of cardiovascular events, is about 6–8%. About
40% of patients with “asymptomatic” carotid stenosis have
coincident coronary artery disease (CAD) [10, 43, 44]. In
many patients, silent atherosclerotic alterations of coronary
vessels lead to a signiﬁcantly increased mortality. ACAS
showed a mortality rate of 6% with one year of followup
[5]. The highest prevalence (28%) of carotid stenosis was
found in patients with peripheral artery disease (PAD); these
patients also have the highest mortality [2].
In our patient group described above, about one-fourth
of the patients (38; 24.1%) had CAD and 18 (11.4%) PAD.
There was even a statistically signiﬁcant correlation between
grade of stenosis and presence of CAD (P = 0.018).
Classic vascular risk factors were very common: arterial
hypertension (140; 88.6%), hyperlipidemia (77; 48.7%), and
diabetes mellitus (54; 34.2%).
ACAS and ACST could show a minor preventive eﬀect
of carotid surgery in carotid stenosis between 60% and
99%. A reﬁned assessment of risk according to stenosis
grade could not be made because of various methodological
problems. In ACAS, absolute risk reduction of stroke and/or
death was 5.9% and in ACST 5.4%, in a time frame of
5 years. However, it should be taken into considerationStroke Research and Treatment 5
Table 3: Factors that increase stroke risk in patients with carotid
stenosis.
Acute hemispheric ischemia associated with carotid stenosis in
the last 4 weeks
Ipsilateral silent infarcts in CT/MRI
Intracranial artery stenosis
Contralateral carotid occlusion
Insuﬃcient medical treatment (risk factors)
Insuﬃcient collateralisation over the circulus Willisii
Coexistent coronary/peripheral artery disease
Leukoaraiosis
HITS detection
Rapid progression of carotid stenosis
Plaque ulcerations
Highly echolucent plaques in carotid duplexsonography
High Lp-PLA2 Concentration
that the perioperative complication risk in both studies was
extremely low (2.3% and 2.9%), because of a very strict
selectionofsurgeons[5,6].Nevertheless,manypatientswere
treated unnecessarily because of the large number needed to
treat (17–19).
Control of risk factors was reported in ACST on a retro-
spective analysis suggesting that the already small beneﬁt of
surgery was minimized or lost if adequate monitoring of risk
factor management had been achieved [6, 45].
Results from studies with very long followups from our
department support these ﬁndings of low stroke mortality
rate in these patients [10, 46].
7. New Assessment of Prognosis
and Management
Based on the available data [47–51] ,an u m b e ro ff a c t o r s
associated with a high risk of stroke on the basis of a carotid
stenosis can be identiﬁed (Table 3).
Associated with low risk of stroke are Retinal TIA,
no (or few) vascular risk factors, eﬀective intracranial
collateralisation over the circulus Willisii, as well as subtotal
stenosis [52–54].
Indications of an unstable (“vulnerable”) plaque are
plaque ulcerations, high concentration of lipoprotein-
associated phospholipase A2 (Lp-PLA2), and highly echolu-
cent plaques [55–59].
Beside the simple clinical risk score ABCD2 (age, blood
pressure, clinical features, duration, diabetes) [60], the risk
modelproposedbyRothwellcanhelptoassesstheindividual
risk for ipsilateral cerebrovascular events in patients with
carotid stenosis [54, 61]. It is based on meta-analysis data
of the major carotid studies (particularly the ECST) and
may support in making an individual treatment decision
(Table 4).
8. Conclusions
Uncritical usage of the results from the aforementioned
studies often misguides and leads to false conclusions,
generalizations, and uncertainty about best available mod-
ern treatment. This problem rises at least partly from
the diﬀerent methods used to evaluate the stenosis grade
(angiography versus ultrasound) and from the nonvalidated
evaluation criteria. Therefore, ACAS and ACST could not
show any connection between stenosis grade and stroke
risk, whereas this connection was clearly shown not only
in natural history studies but also in NASCET and ECST.
Because patients nowadays do not usually undergo con-
ventional angiography before carotid surgery, the direct
justiﬁcation for surgery by these studies’ results is actually
missing.
Other problems and insecurities in the management
of carotid stenosis result from the fact that a signiﬁcantly
positive eﬀect of carotid surgery (in NASCET and ECST)
was shown only in patients who underwent surgery within
2–4 weeks, but not in those operated upon later, up to 4–
6 months. Furthermore, there are signiﬁcant asymmetries
in the recruitment of men/women in all 4 major studies.
These asymmetries were not corrected in the analysis of
the primary endpoints, thus undermining the results of
ACAS and ACST in particular [62]. Possible overlapping
of diﬀerent stroke pathogenesis was not taken into con-
sideration, which limits the direct transfer of study results
to the individual patient in everyday clinical practice. In
our patient collective, for example, carotid stenosis was the
probable cause of stroke in less than half of patients and
even in part of these patients there was an overlapping with
other (mostly cardiac) causes. The ASCO score is especially
suitable to demonstrate overlapping stroke etiologies and to
quickly create a rudimental risk proﬁle of the patient [42].
Often lacking a suﬃcient brain imaging (especially MRI)
and thorough stroke workup, as it is performed today before
every carotid surgery, the studies failed to take some of these
factors into account. Finally, adequate medical management
with monitoring and controlled treatment of vascular risk
factors (e.g., statin and/or antihypertensive treatment) was
missed.
A strict classiﬁcation in “symptomatic” and “asymp-
tomatic” carotid stenosis and decisions on the degree of
carotid stenosis alone could therefore be misleading. Carotid
disease should be rather regarded as an entity with active
and stable phases. When deciding about treatment, one
should diﬀerentiate between those two phases utilizing
clinical ﬁndings, followups (e.g., rapid progression, repeated
TIAs), or other parameters (silent infarcts in brain imaging,
HITS, plaque conﬁguration). During an active phase, carotid
surgery is advisable under the condition that it is performed
early and that the perioperative complication risk is low
(<5%) [47, 63]. Carotid angioplasty with or without stent
is currently not a routine option but can be performed
by highly experienced interventionalists in selected patients
who cannot undergo a surgery. None of the major studies6 Stroke Research and Treatment
Table 4:RiskmodelbyRothwellforipsilateralterritorialinfarctsinallpatientsinthemedicaltreatmentbranchofECST[61].CI:conﬁdence
interval.
P Hazard ratio 95% CI
Cerebral events versus ocular events 0.008 2.45 1.27–4.75
Residual neurological signs after 7 days 0.006 1.30 1.08–1.57
Diabetes 0.007 1.82 1.18–2.80
Any ischemic event within the last 2 months 0.003 1.71 1.20–2.44
Number of events within the last 3 months (per event) 0.01 1.02 1.01–1.03
Previous myocardial infarction 0.02 1.31 1.04–1.65
Degree of carotid stenosis 0.0000 1.34 1.30–1.38
Plaque surface irregularity 0.01 1.80 1.14–2.83
Poststenotic collapse of the internal carotid artery 0.03 0.40 0.17–0.94
Age (per year) 0.62 1.01 0.98–1.03
Male sex 0.31 1.23 0.83–1.82
Systolic blood pressure (per 10 mmHg) 0.82 1.05 0.90–1.15
Diastolic blood pressure (per 10 mmHg) 0.61 1.10 0.80–1.30
Peripheral vascular disease 0.90 1.03 0.65–1.63
Angina without previous myocardial infarction 0.77 0.96 0.71–1.29
ECG signs of left ventricular hypertrophy 0.90 1.07 0.40–2.10
Cerebral infarct on symptomatic side on CT 0.18 1.32 0.88–1.96
Occlusion of the contralateral internal carotid artery 0.96 1.00 0.72–1.63
until today (SPACE, EVA3S, CAVATAS, ICSS, CREST) could
show a noninferiority of angioplasty compared with carotid
surgery [64, 65].
During a stable phase, the patient with carotid stenosis is
apatientinhighriskforcardiovascularevents.Inaccordance
with results from previous studies [10, 43, 44], our patients
had a high percentage of concomitant vascular diseases and
risk factors. Almost all patients had an arterial hypertension,
and hyperlipidemia and diabetes were also very common.
Furthermore, PAD and CAD were quite common, and the
presence of CAD even correlated with the grade of carotid
stenosis. The risks derived from these diseases are not
diminished by a surgical or interventional treatment of the
carotid stenosis [52]. Because of the high cardiovascular risk,
however, these patients do proﬁt from controlled medical
treatment. Every risk factor increases vascular risk by its
own, so there is a summation eﬀect of their combined
treatment on the prognosis [66]. Particularly under statin
treatment, it could be shown that not only there is a
reduction of TIA/stroke and of cardiovascular morbidity
and mortality associated with coincidental coronary heart
disease but also a decrease in the necessity of vascular
interventions (56% of relative risk reduction) [67]. SPACE2
will possibly clarify if there is need of an interventional
carotid treatment in these cases. Other cerebrovascular risk
factors, such as atrial ﬁbrillation, should certainly be also
taken into consideration. Conservative treatment strategies
and duplex sonographic followups (in most cases every 3–6
months) are essential in order to detect a phase of activity in
time.
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